Search Result

Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Humanized Single Domain Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (1) SARS-CoV (1)
By Research Areas:	Cancer (1) Infection (1)

2

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

Targets Recommended: ADC Antibody Discoidin Domain Receptor Epigenetic Reader Domain Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC WDR5 PIKfyve BCL6

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

Anti-Spike-RBD Single Domain mAb SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

Cat. No.	Product Name	Target	Research Area

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

Anti-Spike-RBD Single Domain mAb SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

Cat. No.	Product Name	Category	Target	Chemical Structure

Envafolimab ASC 22; KN 035	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us